Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors

Cancer Research

Volumn 65, Issue 19, 2005, Pages 8698-8705

  Castillero Trejo, Yeny ^a   Eliazer, Susan ^a   Xiang, Lilin ^a   Richardson, James A ^b   Ilaria Jr , Robert L ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P21; PROTEIN P53; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BONE TUMOR; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL IMMORTALIZATION; CELL LINEAGE; CELL STRUCTURE; CELL TRANSFORMATION; CHILDHOOD CANCER; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; EWING SARCOMA; GENE EXPRESSION; GENE MUTATION; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE EWS; ONCOGENE FLI 1; PRIORITY JOURNAL; SARCOMA; STEM CELL; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; ANIMALS; BONE NEOPLASMS; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING'S;

EID: 25444507396     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1704     Document Type: Article

References (50)

1. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001;20:5747-54.
2. Fechner RE, Mills SE. Small Cell Sarcomas. The atlas of tumor pathology. Third ed. Washington (DC): Armed Forces Institute of Pathology; 1993. p. 187-201.
3. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993;90:5752-6.
4. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders MH 3T3 cells tumorigenic. Nat Genet 1997;17:495-7.
5. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995;11:1049-54.
6. Tanaka K, Iwakuma T, Harirnaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99:239-47.
7. Eliazer S, Spencer J. Ye D, Olson E, Ilaria RL, Jr. Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol Cell Biol 2003;23:482-92.
8. Silvany RE, Eliazer S, Wolff NC. Ilaria RL, Jr. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 2000;19:4523-30.
9. Ilaria RL, Hawley RG, Van Etten RA. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 1999;93:4154-66.
10. Wolff NC, Ilaria RL. Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood 2001;98:2808-16.
11. Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994;14:3230-41.
12. Folpe AL, Gown AM. Immunohistochemistry for analysis of soft tissue tumors. In: Weiss SW, Goldblum JR, editors. Enzinger and Weiss's soft tissue tumors. St. Louis: Mosby: 2001. p. 199-245.
13. Dauphinot L, De Oliveira C, Melot T, et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 2001;20:3258-65.
14. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FL1 induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002;1:393-401.
15. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 2001;20:6731-41.
16. Kovar H, Jug G, Aryee DN, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997;15:2225-32.
17. Maitra A, Roberts H, Weinberg AG, Geradts J. Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch Pathol Lab Med 2001;125:1207-12.
18. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
19. Kovar H, Auinger A, Jug G, et al. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993;8:2683-90.
20. Abudu A, Mangham DC, Reynolds GM, et al. Over-expression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 1999;79:1185-9.
21. Park YK, Chi SG, Kim YW, Park HR, Unni KK. P53 mutations in Ewing's sarcoma, Oncol Rep 2001;8;533-7.
22. Austin S, Ziese M, Sternberg N. A novel role for site-specific recombination in maintenance of bacterial replicons. Cell 1981;25:729-36.
23. Hamilton DL, Abremski K. Site-specific recombination by the bacteriophage P1 lox-Cre system. Cremediated synapsis of two lox sites. J Mol Biol 1984;178:481-6.
24. Sauer B, Henderson N. Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome. Nucleic Acids Res 1989;17:147-61.
25. Torchia EC, Jaishankar S, Baker SJ. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res 2003;63:3464-8.
26. Kovar H, Dworzak M, Strehl S, et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing s sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 1990;5:1067-70.
27. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol 2005;29:1025-33.
28. Carter RL, al-Sams SZ, Corbett RP, Clinton S. A comparative study of immunohistochemical staining for neuron-specific enolase, protein gene product 9.5 and S-100 protein in neuroblastoma, Ewing's sarcoma and other round cell tumours in children. Histopathology 1990;16:461-7.
29. Owen M, Friedenstein AJ. Stromal stein cells: marrow-derived osteogenic precursors. Ciba Found Symp 1988;136:42-60.
30. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970;3:393-403.
31. Bianco P, Riminucci M. Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001;19:180-92,
32. Baddoo M, Hill K, Wilkinson R, et al. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J Cell Biochem 2003;89:1235-49.
33. Short B. Brouard N, Occhiodoro-Scott T, Ramakrishnan A, Simmons PJ. Mesenchymal stem cells, Arch Med Res 2003;34:565-71.
34. Jiang Y, Jahagirdar BN, Reinhardt RL. et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9.
35. Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 2002;30:896-904.
36. Meirelles Lda S, Nardi NB. Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol 2003;123:702-11.
37. Nishimori H, Sasaki Y, Yoshida K, et al. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene 2002;21:8302-9.
38. Scotland K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4.
39. Maksimenko A, Malvy C, Lambert G. et al. Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies. Pharm Res 2003;20:1565-7.
40. Lambert G, Bertrand JR, Fattal E, et al. EWS fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 2000;279:401-6.
41. Kovar H, Aryee DN, Jug G, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996;7:429-37.
42. Green DR, Evan GI. A matter of life and death. Cancer Cell 2002;1:19-30.
43. Armengol G, Tarkkanen M, Virolainen M, et al. Recurrent gains of Iq, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 1997;75:1403-9.
44. Stark B, Mor C, Jeison M, et al. Additional chromosome Iq aberrations and dert(1:16), correlation to the phenotypic expression and clinical behavior of the Ewing family of tumors. J Neurooncol 1997;31:3-8.
45. Maurici D, Perez-Atayde A, Grier HE, Baldini N, Serra M, Fletcher JA. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet Cytogenet 1998;100:106-10.
46. Hattinger CM, Rumpler S, Strehl S, et al. Prognostic impact of deletions at Ip36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 1999;24:243-54.
47. Gazdar AF, Kurvari V, Virmani A, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 1998;78:766-74.
48. Lubbert M, Miller CW, Crawford L, Koeffler HP. p53 in chronic myelogenous leukemia. Study of mechanisms of differential expression. J Exp Med 1988;167:873-86.
49. Guo K, Wang J, Andres V, Smith RC, Walsh K. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol 1995;15:3823-9.
50. Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995;267:1018-21.